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Summary Sera drawn from; healthy individuals, patients with squamous cell carcinoma (SCC) of the
oesophagus and patients with mild active oesophagitis were examined for autoantibodies to cytoskeletal
proteins extracted from the normal oesophageal keratinocyte or from 2 carcinoma cell lines, each of the latter
have a simple cytoskeleton.
Using a radioimmunoassay with normal oesophageal cytokeratins as bound antigen, 86 normal, 76 SCC
and 14 oesophagitis sera were compared. No significant difference in autoantibody titre was found. When the
bound antigen was changed to one containing predominantly simple epithelial cytokeratins a significant
increase (32% P<0.001) was noted in the SCC category only.
Western blots using simple epithelial cell extracts as antigen revealed autoantibodies to cytokeratins 8, 18
and 19 as well as to one other unidentified protein in most SCC sera, and in some normal sera. Antibodies
to cytokeratin 18 predominated.
Normal and SCC sera were applied using indirect immunofluorescent techniques to normal oesophageal
keratinocytes, SNO oesophageal SCC cells and HeLa cells grown in vitro. Autoantibodies to oesophageal
cytokeratins were, with few exceptions, barely detectable. Strong reactions were noted against SNO and HeLa
cytoskeletal components, but also against nuclear membrane and nucleolar determinants.
These experiments suggest that raised levels of autoantibodies to certain cytoskeletal and nuclear
determinants may be a feature of oesophageal cancer.
An autoimmune response occurs when the immune system is
exposed to antigens normally found within the cell. It is a
common phenomenon in diseased patients, as well as normal
healthy individuals (Christian & Elkon, 1986; Serre et al.,
1987; Iwatsuki et al., 1986; Passaleva et al., 1986). Autoanti-
bodies against intracellular antigens can be broadly subdi-
vided into two groups, (a) nuclear and (b) cytoplasmic. The
nuclear group comprises autoantibodies to DNA, histones,
non-histone proteins and nucleolar antigens. These anti-
bodies could be described as having a loose association with
rheumatic and blood diseases (Passaleva et al., 1986;
Christian & Elkon, 1986). On the other hand, the cytoplas-
mic group is primarily represented by autoantibodies against
constituents of the three cytoskeletal systems: the micro-
filaments, microtubules and the intermediate filaments
(Alcover et al., 1985; Senecal et al., 1985; Zauli et al., 1985).
Circulating antibodies to the microfilaments and micro-
tubules, or actin and tubulin respectively, have been demon-
strated in patients with a variety of liver diseases,
rheumatoid diseases, SLE and in some other less common
syndromes (Kurki et al., 1983a,b; Senecal et al., 1985; Zauli
et al., 1985).
As the cytokeratins comprise the largest subfamily within
the intermediate group of filaments (containing some 20
distinct polypeptides), it is not surprising that autoantibodies
to cytokeratins occur in human sera (Iwatsuki et al., 1986;
Serre et al., 1987). In fact, autoantibodies to epidermal
cytokeratins seem to be a common phenomenon in human
sera. Studies have shown that most, though not all, human
antiepidermal antibodies are directed against cytokeratin
polypeptides characteristic of the basal, suprabasal and
stratum corneum cell layers (Abel & Bystryn, 1976; Paluch &
Bloch, 1982; Hintner et al., 1983; Iwatsuki et al., 1986).
The synthesis of antibodies to cytokeratins specific to
basal or suprabasal epidermal strata appears to be a charac-
teristic of certain epidermal diseases, such as bullous pemphi-
gus (see Viac et al., 1986). However, it has not yet been
established whether raised levels of autoantibodies to cyto-
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keratins in human serum are associated with the presence of
squamous cell carcinoma (SCC).
At present, little or nothing is known about the specificity
of circulating autoantibodies to antigenic components of
stratified squamous epithelia other than the epidermis, for
example, the cytokeratins of the internal organs such as the
oesophagus. It should be noted that the oesophageal epithe-
lium expresses its own distinctive subset of acidic and basic
cytokeratin polypeptides (Moll et al., 1982), a pattern which
is maintained in the associated neoplasms (Moll et al., 1982;
Grace et al., 1985).
Oesophageal SCC has a global distribution but epidemio-
logical studies indicate that, geographically, Africa and in
particular South Africa, has the highest incidence (Rose,
1973; Day, 1975; Harington & Bradshaw, 1978).
Lack of a method for early detection has made treatment
extremely difficult. Palliation is the only form of manage-
ment possible in the vast majority of patients (Mannell,
1982). With a view to solving this problem we compared
levels of autoantibodies to cytokeratins in sera obtained
from patients with oesophageal SCC, or mild active oeso-
phagitis, with sera from individuals clinically free of cancer,
using a quantitative radioimmunoassay, immunoblotting and
immunofluorescence techniques. We have detected a signifi-
cant increase in autoantibodies to simple cytokeratins only in
those patients with oesophageal SCC.
Materials and methods
Serum samples
All serum samples were obtained from patients who pre-
sented at the Gastroenterology Unit of the Baragwanath
Hospital. Informed consent was obtained in each case
(Ethics No. 16/2/87). Experiments were performed simul-
taneously and blind on normal control serum, serum from
patients subsequently shown to have mild oesophagitis, and
serum from patients with histologically confirmed squamous
cell carcinoma (SCC) of the oesophagus. The samples were
unmasked at the end of several experimental runs and the
results pooled and analysed statistically. Two classes of
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control sera were used in the analysis, designated Control I
and Control 2. The former group comprised completely
healthy volunteers whereas the latter were hospital patients
admitted for reasons not in any way related to cancer.
Reproducibility between experiments was found to be extre-
mely good both from extract to extract and between earlier
and later runs. All of the patients were black and fell within
the age range of 39-80 with the mean at 57 years. The male/
female ratio in the sample was 5.6:1. The statistical validity
of the findings was tested using an unpaired Student's t test
on a Hewlett Packard 85 bench top computer.
Extraction of cytokeratin proteins
Oesophageal cytokeratin polypeptides were obtained by
extracting the epithelium scraped from fresh post-mortem
oesophagi. Samples rich in simple epithelial type cytokeratin
polypeptides were obtained by extracting either the human
SNO oesophageal SCC cell line (Bey et al., 1976) or D98
HeLa cells (courtesy of E.J. Stanbridge, University of Cali-
fornia, Irvine) both of which were grown in vitro. All of the
above extracts were produced according to the method of
Franke et al. (1981). Briefly, confluent cell cultures or
epithelial scrapes received a rinse with phosphate buffered
saline (PBS) followed by a rinse with TNE buffer (140mM
NaCl, 1 mM EDTA, 10mM Tris-HCl pH 7.6) containing
1 mM phenyl-methyl-sulphonyl-fluoride (PMSF) and Trasylol
(100 kallikrein units/ml). Cultured cells were then scraped off
the substrate, collected in TNE buffer and pelleted. The
cellular or epithelial pellet was subjected to a two step
extraction procedure. Firstly, resuspension in TNE buffer
containing 1% Triton X-100 for 5min, a TNE wash,
followed by a second extraction of the pellet in TNE
containing 1.5 M KCl and 0.5% Triton X-100 for a period
of 20min. After a further two washes with TNE buffer, the
final sediment was taken up in lysis buffer (Laemmli, 1970);
and boiled for 5min. The extracted cytokeratin proteins were
analysed by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) in a 12.5% vertical slab gel (Laemmli, 1970).
Radioimmunoassay
All radioimmunoassay experiments were performed in tripli-
cate. Nitrocellulose paper discs, 5 mm in diameter (Sartor-
ious SM114), were soaked for 2h in a 1 mgml - solution of
cytoskeletal extract (see above). Protein determination per-
formed on the discs after the 2h soak showed that the discs
consistently adsorbed 5jug protein. Any remaining back-
ground was masked by a 2h treatment with 'blotto' (5%
low-fat dried milk, 0.05% Triton X-100, 0.01% Antifoam A
in 50mM Tris-HCI pH 7.8 (see Hauri & Bucher, 1986) and
the discs then incubated in 1: 10 dilution of human serum for
1 h. This serum dilution was determined by incubating the
discs containing 5pg of protein in serially diluted sera in
order to identify the saturation level. Serum titre producing
maximal binding in 8 randomly chosen sera ranged between
dilutions of 1:250 and 1:10. As a result all tests were
conducted at the 1:10 dilution. After four washes in blotto
(15min per wash) the discs were incubated in 20ml of blotto
containing 2!LCi 125I-protein A (Amersham) for 1 h. Finally
the discs were again washed in blotto as above, rinsed in
PBS, air dried and counted in a Packard Autogamma
counter.
Immunoblotting
Cytokeratin extracts produced as above were separated by
12.5% SDS-PAGE and transferred to nitrocellulose paper at
4°C for 2h (Towbin et al., 1979), and the background
blocked in blotto as above. The nitrocellulose paper was
then divided into 1 cm wide strips and each strip incubated
in 1:50 serum in blotto over night. Strips were washed in 4
changes of blotto over 2h before being incubated in 12511
Protein A for 2h (1,Ci/l0ml in hlotto). Finally the strips
were again washed in blotto as above, air dried and auto-
radiographed on Fuji X-ray plate.
Immunofluorescence
Immunofluorescence procedures were performed essentially
as described by Sun and Green (1978) and Franke et al.
(1978) using human serum diluted at 1:10. Antibody/antigen
complexes were visualised by a two-step method of first
reacting with biotinylated goat anti-human IgG (1:250)
followed thereafter by binding FITC-conjugated streptavidin
(1:200).
Results
Radioimmunoassay experiments (RIA)
Figure 1 shows that the normal oesophageal epithelium
expresses 8 cytokeratin polypeptides; four high MW compo-
nents and four subunits with lower mol. wts (la track 2,
and lb). Although autoantibodies to oesophageal cytokera-
tins were present in the serum from normal healthy subjects
and patients with oesophageal SCC, there was no significant
difference in antibody titre between the groups when the
oesophageal cytokeratins were employed as the bound anti-
gen (Figure 2).
A clear, statistically significant (P<0.001) difference in
autoantibody titre between healthy subjects, and patients
with oesophageal SCC was observed in experiments using
SNO cell extracts (containing cytokeratins (5), 8, 18 and 19
see Figure 3).
Sera from 14 patients with histologically confirmed mild
active oesophagitis were compared with sera from normal
subjects, and patients with oesophageal SCC. As can be seen
from Figure 3, patients with mild active oesophagitis were
no different to healthy subjects with respect to autoantibody
titre against SNO extracts.
In order to establish that the increase in autoantibody titre
was not perhaps against trace amounts of proteins specific to
SNO cells, serum analyses were repeated using extracts from
HeLa cells, which express cytokeratin components 8, 18 and
vimentin (see Figure la track 4 and Id also Moll et al.,
1982). Almost identical values (see Figure 3) were obtained;
a significant increase in autoantibody titre was seen to occur
in the sera from patients with confirmed oesophageal SCC.
This result suggests that the presence of cytokeratins (5), 19
and several distinctive cytoskeletal-associated proteins, which
are present in the SNO, but not in the HeLa extracts, played
no role in the determination of antibody titre. Likewise,
vimentin can be excluded as an autoantigen as it is a major
component of the cytoskeleton in HeLa cells but not in the
SNO cells. This observation makes clear the distinction, on
the basis of autoantibody titre, between SCC and diseases
like SLE where the primary autoantigen is vimentin (Alcover
et al., 1985).
Immunofluorescence studies
The cytokeratin cytoskeletal specificity of the circulating
autoantibodies was confirmed for 62 sera by immunofluores-
cence analyses. Out of the 62 sera only 7 from controls and
11 from patients with oesophageal carcinoma displayed a
relatively strong positive staining reaction on normal human
oesophageal epithelial cells grown in tissue culture. The
fibrous pattern indicative of anticytoskeletal antibodies or a
prominent nucleolar staining was observed in these cases (see
Figure 4).
Both the number of reactive sera, and the intensity of the
staining were increased when the same range of sera were
tested on SNO cells. That is, 10 sera from the normal
controls produced strongly positive results and similarly, 21
sera from patients with carcinoma of the oesophagus. In
most instances the fluorescent patterns produced were of aAUTOANTIBODIES TO OESOPHAGEAL CARCINOMA CYTOKERATINS 769
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Figure 1 One and two dimensional electrophoretic separations of cytokeratin-enriched preparations from normal oesophageal
epithelium and cultured SCC cells. (a) Track I - calibration proteins, phosphorylase b (94kD), bovine serum albumin (67kD),
ovalbumin (43 kD), carbonic anhydrase (30kD), trypsin inhibitor (21.1 kD); Track 2 - normal adult human oesophageal epithelial
scrapes; Track 3 - cultured human oesophageal SNO carcinoma cells; Track 4 - cultured D98 HeLa cells; (b) 2D normal adult
human oesophageal epithelial scrapes; (c) 2D cultured human oesophageal SNO carcinoma cells; (d) 2D cultured D98 HeLa cells.
Note the absence of component 19 in the HeLa separation but the presence of vimentin (v). The arrow indicates actin. The pH
gradient is indicated across the top of the figure (Gel= 12.5%).
filamentous nature although there was also evidence of
granular cytoplasmic, nuclear membrane and nucleolar stain-
ing (see Figure 4). The characteristic staining patterns of
actin and vimentin, which are easily distinguished from the
cytokeratin-type, were never observed. A typical actin or
vimentin fibrous network was absent when immunofluores-
cence was performed on D98 HeLa, cells which synthesize
comparatively large amounts of vimentin (see Figure ld).
Western blotting analyses
Samples of the same SNO extracts, separated by SDS-PAGE
and transferred to nitrocellulose, were used to determine the
specificity of the autoantibodies present in a range of sera.
Of the 28 sera employed in the blotting experiments 10
examples of the various reactions obtained are shown in
Figure 5. All the sera contained autoantibodies which
reacted with cytokeratin 18, and seventy percent with both 8
and 18. Sixty percent of the sera tested contained autoanti-
bodies to a third component in addition to the above two,
viz., cytokeratin 19. Fairly uncommon was the presence of
an antibody to a fourth polypeptide (58 kD mol. wt.,
possibly cytokeratin 5 which occurs in trace amounts in
SNO extracts) which reacted strongly when present. A few of
the sera contained antibodies to an additional high mol. wt.
component (HMW in Figure 5). This is probably not a
cytokeratin since it reacted neither with AEI nor AE3
monoclonal antibodies to cytokeratin (kindly provided by
T.-T. Sun, Department of Dermatology, New York
University).
Discussion
There is only one prior report quantifying serum antikeratin
activity in patients with SCC. In this instance Lambre et al.
(1986) assayed cytokeratin antibodies in sera from patients
with SCC of the lung but were unable to detect a significant
difference from the mean value for a group of normal
controls. Here we show that circulating autoantibodies to the
cytokeratins expressed by the stratified squamous oesopha-
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Figure 2 Autoantibody reaction to normal oesophageal epithe-
lial cytokeratins in the sera of normal healthy subjects and
patients with oesophageal SCC. Cytokeratins 4, 5, 6, 13, 14/15,
16, (17), (18) and 19 appear in normal oesophageal cytokeratin
extracts (see Figure la track 2 and lb). The mean value
represents the amount of 1251 protein A-serum autoantibody
conjugate bound per jig of cytokeratin extract. The difference
between means (A) is uniformly compared with Control 2 (see
Materials and methods). Ag=extract used as the bound antigen.
bkg=the level of background in the radioimmunoassay.
Ag = SNO/HeLa cytoskeletal proteins
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Figure 3 Autoantibody reaction to cytoskeletal extracts of cul-
tured SCC cells in the sera of normal healthy subjects, patients
with oesophageal SCC and patients with mild active oesophagi-
tis. SNO cytoskeletal extracts contain cytokeratins (5), 8, 18 and
19 in almost equal quantities (see Figure la track 3 and lc).
HeLa extracts contain cytokeratins 8 and 18 together with large
quantities of vimentin (v) intermediate filament protein (see
Figure la track 4 and ld). The mean value represents the
amount of 125I protein A-serum autoantibody conjugate bound
per jg of cytoskeletal extract. The difference between means (A)
is uniformly compared with Control 2 (see Materials and
methods). Ag=extract used as the bound antigen. bkg=the level
of background in the radioimmunoassay.
Figure 4 Indirect immunofluorescent staining of cultured cells. a, b, c: Cultured normal human oesophageal epithelial cells. Note
the different staining patterns obtained with different sera; a - the most common staining pattern being distinctly fibrous with
discernible desmosomal structures; b - nucleolar staining; c - nuclear staining. d, e, f: Cultured human oesophageal SNO
carcinoma cells. Again different staining patterns were obtained with the most common being the fibrous meshwork typical of
cytoskeletal staining. The distinctive staining patterns of vimentin and/or actin were absent. Bar=20jm.
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Figure 5 One dimensional electrophoretic separations of cytokeratin-enriched preparations from SNO oesophageal carcinoma
cells using serum from patients with oesophageal SCC. Track 1 - nitrocellulose paper showing the electrophoretically transferred
cytoskeletal polypeptides stained with fast green; Tracks 2-11 - nitrocellulose-bound SNO carcinoma cell cytoskeletal separation
reacted with various sera from patients with oesophageal SCC, conjugated with 1251 protein-A and visualized by autoradiography.
Note that autoantibodies to cytokeratin polypeptide 18 occur most commonly in the sera from these patients followed by
antibodies against polypeptides 8 and 19. Note also the relatively common appearance of a high mol. wt. (HMW) component as
yet unidentified.
geal epithelium are present in the serum of normal subjects
and patients with SCC of the oesophagus. Using a solid
phase radioimmunoassay, and the set of normal oesophageal
cytokeratins (polypeptides nos. 4, 5, 6, 13, 14/15, 16 and 19)
as the bound antigen, we found no significant difference in
autoantibody titre (Figure 2). An interesting and unexpected
finding was that the autoantibody titre was 32% higher in
patients with oesophageal SCC, when SNO or HeLa extracts
were employed as the antigen. These extracts contain cyto-
keratins 8, 18, and 19 or 8, and 18 respectively. Apparently
trace amounts of cytokeratin 5 (SNO cells) and large
concentrations of vimentin (HeLa cells) played an insignifi-
cant role in the increased antibody binding (see Figure 3).
This study supports the idea that serum autoantibodies to
some types of intermediate filaments can be quantified and
therefore are useful indicators of disease. Alcover et al.
(1985) have shown some time ago that SLE is linked to a
raised autoantivimentin titre.
Several authors have postulated that mild active oesopha-
gitis precedes the onset of oesophageal SCC (Mannell, 1982).
The data presented in Figure 3 show that there is no
difference in the titre of autoantibodies to components of the
simple cytoskeleton when normal, healthy controls, and
patients with histologically confirmed mild active oesophagi-
tis were compared. These observations lead one to conclude
that either mild active oesophagitis may be a condition
unconnected with oesophageal SCC, or that there is an
intermediate step which hitherto has escaped detection. It is
important to note that patients with moderate oesophagitis,
which one has been led to suspect as the next step in the
progression towards SCC (see Mannell, 1982) are normally
very rarely detected. We were able to test only one such case
in this study (1/14=7.1%) the result of which was indis-
tinguishable from the mild cases. Similarly, adenocarcinoma
of the oesophagus forms less than five percent of the cases
presenting at Baragwanath Hospital. Our data are as yet
insufficient to say whether adenocarcinoma and SCC can be
distinguished on the basis of this radioimmunoassay. To date
there is no reliable technique that distinguishes between mild
active oesophagitis and the preneoplastic state, or stages
thereof, as in cancer of the cervix (Raebin, 1983). Clearly
every avenue should be thoroughly explored which could
possibly facilitate a more accurate early diagnosis of the
disease.
Western blotting experiments performed using the sera
from the patients with oesophageal SCC showed that,
although antibodies to each of the simple epithelial cytokera-
tins were present in one or another serum, antibodies to
polypeptide 18 were present throughout (see Figure 5). This
is the first report showing an increased autoantibody titre to
a particular cytokeratin in patients with SCC. Future studies
will show whether autoantibodies to cytokeratin 18 are
associated only with oesophageal SCC or with a variety of
unrelated disorders, and perhaps provide an explanation as
to why cytokeratin 18 is more antigenic than other similar
proteins.
In addition to the identifiable cytokeratin polypeptides,
there was at least one other immunoreactive non-cytokeratin
protein (A. Thornley, unpublished results) present in the
high-salt cytoskeletal residue (see HMW in Figure 5). The
identity of these proteins is at present unknown but it has
been shown that cytoskeletal-associated proteins frequently
co-purify with intermediate filaments (Lieska et al., 1985).
Autoantibodies to cytoskeletal components such as actin,
vimentin, desmin and cytokeratin have been described in
diseases such as SLE, rheumatoid arthritis, liver diseases and
bullous diseases (Kurki et al., 1983a,b; Ordeig & Guardia,
1984; Senecal et al., 1985; Alcover et al., 1985; Hajiroussou
et al., 1985). Patients with oesophageal SCC may have raised
levels of autoantibodies to nuclear as well as cytoskeletal
structures. Nuclear, nuclear membrane and in particular
nucleolar staining were striking features of many of the sera
tested on cultures of normal oesophageal epithelial cells or
SNO cells (Figure 4).
Several authors subscribe to the idea that anticytokeratin
antibodies are formed in response to epithelial cell injury or
death (Kurki & Virtanen, 1984; Zauli et al., 1985; Grubauer
et al., 1986; Hintner et al., 1987). A similar event could
account for our results. The most difficult observation to
explain is why antibodies should form predominantly to the
simple epithelial cytokeratins, and to number 18 in particu-
lar. Previously we reported atypical cytokeratin expression in
vitro by a human oesophageal SCC cell line (Veale &
Thornley, 1984). This involved the synthesis of a cytokeratin
profile which was distinctly simple epithelial-like in nature
consisting of polypeptides 8, 18 and 19 with trace amounts
of 5 also present (see Figure la track 3 and 1c, confirmed
using antibodies AEI and AE3, Thornley unpublished
results). Terry et al. (1986) have now reported the presence
of simple cytokeratins in primary oesophageal tumours, but
this is not true for SCCs in general (Moll et al., 1983;
Rheinwald et al., 1984) or oesophageal SCCs in particular
(Grace et al., 1985; Van Muijen et al., 1986). Nevertheless, it
is feasible that the oesophageal SCC tumour itself is the
source of immunoreactive intracellular antigens, possibly in
the form of tissue polypeptide antigen (TPA), now known to
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comprise epitopes found on cytokeratins 8, 18 and 19
(Weber et al., 1984). However, other likely candidates cannot
be ignored, such as the surrounding mesothelium, which
characteristically expresses simple type cytokeratins, or even
viral epitopes which are sufficiently similar to illicit autoim-
mune responses through molecular mimicry (Oldstone, 1987).
These investigations were supported by grants from the National
Cancer Association of South Africa and the URC, University of the
Witwatersrand, Johannesburg, South Africa.
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